文献速递血管炎其他结缔组织病

托珠单抗单药与联合治疗大动脉炎相关巨细胞动脉炎:196例多中心开放研究影像学缓解因素

Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients.
PubMed 文献 · Semin Arthritis Rheum · 2025-11-06

这项多中心观察性研究纳入196例巨细胞动脉炎相关大动脉炎患者,比较托珠单抗单药(136例)与联合csDMARDs(60例)的疗效与安全性。24个月时联合组影像学缓解率50.0% vs 单药组15.8%(p=0.026),联合组影像学缓解的OR为5.26(95%CI 1.03-26.85;p=0.046),临床缓解与EULAR缓解无显著差异,联合组显示泼尼松节约效应,严重不良事件率数值上更低但无统计学差异。

要点

  • 24个月影像学缓解率联合组50.0% vs 单药组15.8%(p=0.026)。
  • 联合治疗使影像学缓解的OR为5.26(95%CI 1.03-26.85;p=0.046)。
  • 临床缓解与EULAR缓解两组无显著差异,联合组有泼尼松节约效应。

核心结论

  • 在GCA-aortitis患者中,TCZ联合csDMARDs在实现影像学缓解和促进糖皮质激素减量方面可能优于TCZ单药,但尚无明确证据表明可减少严重不良事件。

研究设计与样本

  • 多中心观察性研究,比较TCZ联合csDMARDs(TCZcombo)与TCZ单药(TCZmono),共纳入196例GCA-aortitis患者(148例女性,48例男性;136例TCZmono,60例TCZcombo)。
  • 评估12个月和24个月结局,包括临床缓解、EULAR定义缓解、影像学缓解、泼尼松节约效应和安全性;采用多因素logistic回归识别24个月影像学缓解相关因素。

主要发现

  • 24个月时影像学缓解率TCZcombo组50.0% vs TCZmono组15.8%(p=0.026)。
  • 临床缓解和EULAR定义缓解两组无显著差异。
  • TCZcombo显示泼尼松节约效应。
  • 严重不良事件率TCZcombo组数值上低于TCZmono组(8.7 vs 13.2每100患者年;p=0.21)。
  • TCZcombo使影像学缓解的OR为5.26(95%CI 1.03-26.85;p=0.046)。

关键数值与推荐

  • 24个月影像学缓解率:TCZcombo组50.0% vs TCZmono组15.8%(p=0.026)。
  • 影像学缓解OR:5.26(95%CI 1.03-26.85;p=0.046),TCZcombo vs TCZmono。
  • 严重不良事件率:TCZcombo组8.7 vs TCZmono组13.2每100患者年(p=0.21)。

临床怎么用

  • 在GCA-aortitis真实世界实践中,TCZ联合csDMARDs可能较TCZ单药更有利于实现影像学缓解和减少糖皮质激素用量。
  • TCZ联合csDMARDs与TCZ单药在临床缓解和EULAR定义缓解方面无显著差异。
  • 关于TCZ联合csDMARDs是否减少严重不良事件,尚无明确证据。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortitis is a frequent and potentially serious complication of giant cell arteritis (GCA). The phenotype associated with aortitis (GCA-aortitis) can present greater therapeutic challenges than the cranial-dominant phenotype. Tocilizumab (TCZ) is approved for GCA, although its efficacy in GCA-aortitis has not been specifically assessed in randomized controlled trials. OBJECTIVE: To assess the effectiveness and safety of TCZ monotherapy (TCZmono) compared with TCZ plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (TCZcombo) in patients with GCA-aortitis in real-world practice, and to identify variables associated with imaging remission. METHODS: A multicenter observational study comparing TCZcombo versus TCZmono. Outcomes at 12 and 24 months included clinical remission, EULAR-defined remission, imaging remission, prednisone-sparing effect, and safety. Multivariable logistic regression identified factors linked to imaging remission at 24 months. RESULTS: A total of 196 patients (148 female, 48 male) with GCA-aortitis received TCZ (136 TCZmono, 60 TCZcombo). At 24 months, imaging remission was higher in the TCZcombo group (50.0%¦vs. 15.8%; p=0.026). No significant differences were found in clinical or EULAR-defined remission. TCZcombo demonstrated a prednisone-sparing effect. The serious adverse event (SAE) rate was numerically lower with TCZcombo (8.7 vs. 13.2 per 100 patient-years; p=0.21). TCZcombo increased the odds of imaging remission 5.26-fold (odds ratio [OR] 5.26; 95% confidence interval [CI]: 1.03-26.85; p=0.046). CONCLUSION: In patients with GCA-aortitis, TCZcombo may be more effective than TCZmono in achieving imaging remission and promoting glucocorticoid tapering, but without definitive evidence regarding a reduction of serious adverse events.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Martín-Gutiérrez A, Loricera J, Prieto-Peña D, et al. Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients. Semin Arthritis Rheum. 2025. PMID: 41218409. doi:10.1016/j.semarthrit.2025.152869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。